JP2019206593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019206593A5 JP2019206593A5 JP2019165337A JP2019165337A JP2019206593A5 JP 2019206593 A5 JP2019206593 A5 JP 2019206593A5 JP 2019165337 A JP2019165337 A JP 2019165337A JP 2019165337 A JP2019165337 A JP 2019165337A JP 2019206593 A5 JP2019206593 A5 JP 2019206593A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- individual
- paclitaxel
- platinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 14
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 229960001592 Paclitaxel Drugs 0.000 claims 7
- 229910052697 platinum Inorganic materials 0.000 claims 7
- 229930003347 taxol Natural products 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 102100001249 ALB Human genes 0.000 claims 5
- 101710027066 ALB Proteins 0.000 claims 5
- 229940050528 albumin Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 201000005244 lung non-small cell carcinoma Diseases 0.000 claims 4
- 230000035533 AUC Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 1
- 229960004562 Carboplatin Drugs 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
Claims (17)
- 個体のNSCLCを処置するための、パクリタキセルおよびアルブミンを含むナノ粒子を含む医薬組成物であって、該医薬組成物は白金系薬剤と組み合わせて使用され、該処置が、該個体が4つまたはそれ超の転移部を有することに基づく、医薬組成物。
- 前記処置が、前記個体が少なくとも約70歳であることにさらに基づく、請求項1に記載の医薬組成物。
- 前記個体が、該個体が4つまたはそれ超の転移部を有することに基づいて処置のために選択されている、請求項1または2に記載の医薬組成物。
- 前記個体が、該個体が少なくとも約70歳であることに基づいて処置のためにさらに選択されている、請求項1から3のいずれか一項に記載の医薬組成物。
- 前記処置が、前記個体が扁平上皮癌を有することに基づく、請求項1から4のいずれか一項に記載の医薬組成物。
- パクリタキセルおよびアルブミンを含むナノ粒子を含む前記組成物中のパクリタキセルの用量が、約50mg/m 2 から約125mg/m 2 の間である、請求項1から5のいずれか一項に記載の医薬組成物。
- パクリタキセルおよびアルブミンを含むナノ粒子を含む前記組成物が週1回投与されることを特徴とする、請求項1から6のいずれか一項に記載の医薬組成物。
- 前記白金系薬剤の有効量が、約AUC=2から約AUC=6の間である、請求項1から7のいずれか一項に記載の医薬組成物。
- 前記白金系薬剤が3週間に1回投与されることを特徴とする、請求項1から8のいずれか一項に記載の医薬組成物。
- パクリタキセルおよびアルブミンを含むナノ粒子を含む前記組成物中のパクリタキセルの用量が100mg/m 2 であって週1回投与され、前記白金系薬剤の有効量がAUC=6であって3週間に1回投与されることを特徴とする、請求項1から9のいずれか一項に記載の医薬組成物。
- 前記ナノ粒子中のパクリタキセルが、アルブミンでコーティングされている、請求項1から10のいずれか一項に記載の医薬組成物。
- 前記組成物中の前記ナノ粒子が、約200nm以下の平均直径を有する、請求項1から11のいずれか一項に記載の医薬組成物。
- 前記NSCLCが、ステージIIIBのNSCLCまたはステージIVのNSCLCである、請求項1から12のいずれか一項に記載の医薬組成物。
- 前記医薬組成物ならびに前記白金系薬剤が非経口的に投与されることを特徴とする、請求項1から13のいずれか一項に記載の医薬組成物。
- 前記医薬組成物ならびに前記白金系薬剤が静脈内に投与されることを特徴とする、請求項1から14のいずれか一項に記載の医薬組成物。
- 前記白金系薬剤がカルボプラチンである、請求項1から15のいずれか一項に記載の医薬組成物。
- 前記個体がヒトである、請求項1から16のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361778299P | 2013-03-12 | 2013-03-12 | |
US61/778,299 | 2013-03-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018006177A Division JP2018080198A (ja) | 2013-03-12 | 2018-01-18 | 肺がんを処置する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019206593A JP2019206593A (ja) | 2019-12-05 |
JP2019206593A5 true JP2019206593A5 (ja) | 2020-07-02 |
Family
ID=51625117
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016500945A Active JP6349381B2 (ja) | 2013-03-12 | 2014-03-10 | 肺がんを処置する方法 |
JP2018006177A Pending JP2018080198A (ja) | 2013-03-12 | 2018-01-18 | 肺がんを処置する方法 |
JP2019165337A Pending JP2019206593A (ja) | 2013-03-12 | 2019-09-11 | 肺がんを処置する方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016500945A Active JP6349381B2 (ja) | 2013-03-12 | 2014-03-10 | 肺がんを処置する方法 |
JP2018006177A Pending JP2018080198A (ja) | 2013-03-12 | 2018-01-18 | 肺がんを処置する方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10744110B2 (ja) |
EP (2) | EP3698784A1 (ja) |
JP (3) | JP6349381B2 (ja) |
KR (1) | KR102191311B1 (ja) |
CN (2) | CN105228612A (ja) |
CA (1) | CA2903454A1 (ja) |
ES (1) | ES2804323T3 (ja) |
HK (1) | HK1220110A1 (ja) |
IL (1) | IL240935B (ja) |
MX (1) | MX370662B (ja) |
NZ (1) | NZ630392A (ja) |
WO (1) | WO2014159171A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
AU2007334360B2 (en) | 2006-12-14 | 2013-10-17 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
SI2552415T1 (sl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Metode za zdravljenje raka |
US10660965B2 (en) | 2010-03-29 | 2020-05-26 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
SG194623A1 (en) | 2011-04-28 | 2013-12-30 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
MX354859B (es) | 2011-12-14 | 2018-03-23 | Abraxis Bioscience Llc | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
CN110934852A (zh) | 2013-03-14 | 2020-03-31 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
CN116585310A (zh) | 2015-06-29 | 2023-08-15 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
JP6958161B2 (ja) * | 2017-09-20 | 2021-11-02 | コニカミノルタ株式会社 | プリンタ、スキャナプロファイル補正プログラム及びスキャナプロファイル補正方法 |
EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
CN114126660A (zh) * | 2019-01-23 | 2022-03-01 | 锐创生物医药(香港)有限公司 | 药物复合物及其制备方法和用途 |
KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
WO2022221834A2 (en) * | 2021-04-12 | 2022-10-20 | Lantern Pharma Inc. | Method for treating lung cancer and non-small cell lung cancer |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
ES2219646T5 (es) | 1993-02-22 | 2008-11-01 | Abraxis Bioscience, Inc. | Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos. |
US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
JP4865937B2 (ja) | 1997-06-27 | 2012-02-01 | アブラクシス バイオサイエンス、エルエルシー | パクリタキセル製剤 |
AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
WO2000071079A2 (en) | 1999-05-21 | 2000-11-30 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
JP2005503398A (ja) * | 2001-09-13 | 2005-02-03 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 化学塞栓用のパクリタキセルの混合組成物、その油中水型エマルジョン処方物及び製造方法 |
ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
CN100479807C (zh) * | 2002-08-15 | 2009-04-22 | 刘云清 | 药物输送系统——固体纳米药物的制备方法 |
WO2004052401A2 (en) | 2002-12-09 | 2004-06-24 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
US20050004002A1 (en) | 2002-12-09 | 2005-01-06 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
RU2452482C2 (ru) | 2005-02-18 | 2012-06-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Комбинация и способы введения терапевтических средств и комбинированной терапии |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
TWI429452B (zh) | 2005-08-31 | 2014-03-11 | Abraxis Bioscience Llc | 包含弱水溶性藥劑及抗微生物劑之組合物 |
US8143236B2 (en) | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
WO2008027055A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
AU2007334360B2 (en) | 2006-12-14 | 2013-10-17 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
JP2010520289A (ja) | 2007-03-07 | 2010-06-10 | アブラクシス バイオサイエンス, エルエルシー | 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子 |
WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
WO2010118365A1 (en) | 2009-04-10 | 2010-10-14 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses therof |
ES2668837T3 (es) | 2008-12-11 | 2018-05-22 | Abraxis Bioscience, Llc | Terapia de combinación que incluye un taxano y un agente terapéutico adicional |
BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
SG178873A1 (en) | 2009-08-25 | 2012-04-27 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
JP2013511549A (ja) | 2009-11-20 | 2013-04-04 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | ヘッジホッグ関連癌の治療のための方法及び組成物 |
NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
US10660965B2 (en) | 2010-03-29 | 2020-05-26 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
SI2552415T1 (sl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Metode za zdravljenje raka |
JP2013527232A (ja) | 2010-06-02 | 2013-06-27 | アブラクシス バイオサイエンス, エルエルシー | 膀胱がんの処置方法 |
SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
CA2801891C (en) | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
SG194623A1 (en) | 2011-04-28 | 2013-12-30 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
MX354859B (es) | 2011-12-14 | 2018-03-23 | Abraxis Bioscience Llc | Uso de excipientes polimericos para liofilizacion o congelacion de particulas. |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
NZ630239A (en) | 2013-02-11 | 2017-08-25 | Abraxis Bioscience Llc | Methods of treating melanoma |
EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
EP2968253A4 (en) | 2013-03-13 | 2016-11-02 | Abraxis Bioscience Llc | METHODS OF TREATING PEDIATRIC SOLID TUMOR |
CN110934852A (zh) | 2013-03-14 | 2020-03-31 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
US20180064679A1 (en) | 2015-03-05 | 2018-03-08 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
CN116585310A (zh) | 2015-06-29 | 2023-08-15 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
KR20180019229A (ko) | 2015-06-29 | 2018-02-23 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법 |
AU2016285727B9 (en) | 2015-06-29 | 2021-09-30 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
CN107921050A (zh) | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
US20180374583A1 (en) | 2017-05-16 | 2018-12-27 | Abraxis Bioscience, Llc | Nomogram and survival predictions for pancreatic cancer |
-
2014
- 2014-03-10 EP EP20167533.7A patent/EP3698784A1/en not_active Withdrawn
- 2014-03-10 MX MX2015011752A patent/MX370662B/es active IP Right Grant
- 2014-03-10 CA CA2903454A patent/CA2903454A1/en not_active Abandoned
- 2014-03-10 KR KR1020157027993A patent/KR102191311B1/ko active IP Right Grant
- 2014-03-10 ES ES14776420T patent/ES2804323T3/es active Active
- 2014-03-10 EP EP14776420.3A patent/EP2968254B1/en not_active Revoked
- 2014-03-10 CN CN201480027000.9A patent/CN105228612A/zh active Pending
- 2014-03-10 JP JP2016500945A patent/JP6349381B2/ja active Active
- 2014-03-10 WO PCT/US2014/022341 patent/WO2014159171A1/en active Application Filing
- 2014-03-10 NZ NZ630392A patent/NZ630392A/en unknown
- 2014-03-10 CN CN201910705763.9A patent/CN110279864A/zh active Pending
- 2014-03-10 US US14/772,335 patent/US10744110B2/en active Active
-
2015
- 2015-08-31 IL IL240935A patent/IL240935B/en active IP Right Grant
-
2016
- 2016-07-08 HK HK16108024.5A patent/HK1220110A1/zh not_active IP Right Cessation
-
2018
- 2018-01-18 JP JP2018006177A patent/JP2018080198A/ja active Pending
-
2019
- 2019-09-11 JP JP2019165337A patent/JP2019206593A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019206593A5 (ja) | ||
JP2016512506A5 (ja) | ||
JP2013527232A5 (ja) | ||
JP2016513097A5 (ja) | ||
JP2017149726A5 (ja) | ||
JP2016513657A5 (ja) | ||
AU2007317859B2 (en) | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer | |
KR101625347B1 (ko) | 치료제의 조합 및 투여 방식, 및 조합 요법 | |
JP2013523656A5 (ja) | ||
JP2017025090A5 (ja) | ||
JP2018111728A5 (ja) | ||
JP2013527233A5 (ja) | ||
JP2016506908A5 (ja) | ||
JP2019507797A5 (ja) | ||
JP2013503174A5 (ja) | ||
JP2012506448A5 (ja) | ||
CL2018002914A1 (es) | Formas de dosificación de liberación modificada disuasivas de abuso. | |
JP2010514787A5 (ja) | ||
KR20180043356A (ko) | 담관암의 치료법 | |
JP2010529025A5 (ja) | ||
JP2013542205A5 (ja) | ||
JP2020523356A5 (ja) | ||
JP2017503014A5 (ja) | ||
JP2020516646A5 (ja) | ||
MX2018014576A (es) | Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. |